<DOC>
	<DOCNO>NCT01957579</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability MEDI-551 Japanese patient relapse refractory advanced B-cell malignancy .</brief_summary>
	<brief_title>A Phase 1 , Dose-escalation Study MEDI-551 Japanese Adult Patients With Relapsed Refractory Advanced B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Japanese men woman least 20 year age Histologically confirm CLL ( exclude small lymphocytic lymphoma ( SLL ) ) , DLBCL , FL , MM . Karnofsky Performance Status ≥70 ; Life expectancy ≥12 week Any available standard line therapy know lifeprolonging lifesaving Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic hormonal therapy treatment cancer Previous therapy direct CD19 , monoclonal antibody MAb conjugate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase I</keyword>
	<keyword>advanced</keyword>
	<keyword>B cell malignancy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>CD19</keyword>
	<keyword>Japanese</keyword>
</DOC>